7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline: Properties & Uses
7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline: Properties & Uses
7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline is a versatile halogenated quinazoline building block widely employed in medicinal chemistry for the synthesis of kinase inhibitors and other biologically active compounds.
- Chemical Name
- 7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline
- SKU
- D730195
- Core Scaffold
- Quinazoline (bicyclic pyrimidine-fused benzene ring system)
- Key Functional Groups
- 2,4-dichloro (electrophilic substitution sites), 6-methoxy, 7-benzyloxy (orthogonal protecting group)
- Primary Application
- Intermediate for synthesis of EGFR and other kinase inhibitors
- Supplier
- Aladdin Scientific
Chemical Structure and Key Features
7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline belongs to the quinazoline family of bicyclic nitrogen-containing heterocycles, comprising a benzene ring fused to a pyrimidine ring. The compound carries three strategically positioned substituents: two chlorine atoms at the 2- and 4-positions, a methoxy group at the 6-position, and a benzyloxy protecting group at the 7-position.
The 2,4-dichloro pattern is particularly significant in synthetic chemistry. The C-4 chlorine is generally more electrophilically reactive than the C-2 chlorine due to electronic activation by the ring nitrogen atoms, enabling sequential and selective nucleophilic aromatic substitution (SNAr) reactions. This differential reactivity allows chemists to introduce different amine or other nucleophilic fragments in a stepwise fashion, providing precise control over the final molecular architecture.
The 7-benzyloxy group serves as an orthogonally removable protecting group for a phenol, readily cleaved by catalytic hydrogenolysis (e.g., Pd/C, H₂), which can then liberate a free hydroxyl for further functionalization. The 6-methoxy group, by contrast, is typically retained in the final target molecule and contributes to binding interactions and physicochemical properties of the product.
Synthesis and Reactivity
This compound is commonly prepared from the corresponding quinazolinedione or uracil-type precursor through a chlorination sequence using reagents such as phosphorus oxychloride (POCl₃), often in the presence of a base or catalytic amount of a tertiary amine. The benzyloxy group is typically introduced prior to chlorination as part of building the quinazoline ring or via O-benzylation of the corresponding hydroxyl precursor.
In downstream synthesis, 7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline undergoes facile SNAr at the 4-position with primary or secondary amines under mild conditions to give 4-aminoquinazoline intermediates. Subsequent reaction at the 2-position, either with a second amine or another nucleophile under more forcing conditions, provides access to 2,4-diaminoquinazolines or mixed 2-amino-4-chloro intermediates. Alternatively, the 7-benzyloxy group may be cleaved at various stages of the synthesis to introduce phenolic ether substituents or to enable coupling reactions.
Researchers should handle this compound in a well-ventilated fume hood, as chlorinated heterocycles can be irritants. Standard laboratory personal protective equipment (PPE) including gloves, goggles, and lab coat is recommended. Storage under dry, cool conditions away from moisture is advised to prevent hydrolysis of the C–Cl bonds.
Research Applications in Drug Discovery
Quinazoline derivatives bearing 6-methoxy and 7-oxy substituents at defined positions represent a well-established structural class in targeted cancer therapy. The 4-anilinoquinazoline motif is found in several approved tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR) family. 7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline (SKU D730195) provides a convenient entry point for generating analogues within this pharmacophore space.
Medicinal chemists use this intermediate to explore structure–activity relationships (SAR) around the quinazoline scaffold by varying the substituents introduced at the 2- and 4-positions. The orthogonal protecting group at C-7 also allows deprotection and further diversification at a late stage of synthesis, enabling efficient library generation via parallel synthesis approaches.
Beyond EGFR-focused programs, quinazoline building blocks like this compound are explored in research targeting other receptor tyrosine kinases, as well as non-kinase biological targets, making this intermediate broadly useful across multiple therapeutic areas under investigation.
Ordering and Handling Information
7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline is available from Aladdin Scientific under SKU D730195. Researchers and procurement teams should consult the current product page or contact Aladdin Scientific directly for up-to-date information on available pack sizes, pricing, purity specifications, and certificate of analysis (CoA) documentation.
For handling, store the compound in a tightly sealed container under cool, dry, and dark conditions. Avoid exposure to moisture and strong nucleophiles that could react with the reactive C–Cl bonds. Consult the Safety Data Sheet (SDS) for full hazard classification, first-aid measures, and disposal guidance prior to use.
Frequently asked questions
What makes the 4-position chlorine more reactive than the 2-position chlorine in this compound?
In quinazolines, the nitrogen atoms at positions 1 and 3 create an electron-deficient ring system. The C-4 position is particularly activated toward nucleophilic aromatic substitution (SNAr) because it is flanked by two ring nitrogen atoms that stabilize the Meisenheimer complex intermediate, whereas C-2 is activated by only one adjacent nitrogen in the transition-state resonance pathway under typical reaction conditions. This difference allows selective mono-substitution at C-4 first.
How can the 7-benzyloxy protecting group be removed, and when should this step be performed?
The benzyloxy group is typically removed by catalytic hydrogenolysis using palladium on carbon (Pd/C) under a hydrogen atmosphere, which cleaves the O-benzyl bond to liberate the free phenol and toluene as a by-product. This deprotection is generally performed after the nucleophilic substitutions at C-2 and C-4 are complete, since those steps may involve conditions incompatible with a free hydroxyl group. The timing can be adjusted according to the overall synthetic strategy.
Is 7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline suitable as a direct EGFR inhibitor, or is it strictly a synthetic intermediate?
This compound is intended and supplied as a synthetic intermediate rather than a finished pharmacological agent. Its reactive chloro substituents and protective benzyloxy group are characteristic of a building block designed for further chemical elaboration. Researchers use it to construct more complex, drug-like quinazoline derivatives with appropriate substituents for biological evaluation.
What storage conditions are recommended for SKU D730195?
The compound should be stored in a tightly sealed container under cool, dry, and dark conditions to prevent moisture-induced hydrolysis of the C–Cl bonds and to maintain long-term stability. Always consult the certificate of analysis and safety data sheet supplied with the product for specific storage temperature recommendations.
References
- Rewcastle, G. W. et al. Tyrosine kinase inhibitors. Synthesis and structure-activity relationships for inhibitors of epidermal growth factor receptor tyrosine kinase. Journal of Medicinal Chemistry. Review-level background on 4-anilinoquinazolines.
- Chimichi, S. et al. General methods for the synthesis of 2,4-dichloroquinazolines from quinazoline-2,4-diones using phosphorus oxychloride. General textbook-level synthetic procedure reference.
- Aladdin Scientific. Product page: 7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline, SKU D730195. Aladdin Scientific catalog.
Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
危险品化学品经营许可证(带存储)